ArticleFrontiers in pharmacology2026
Effects of sleeve gastrectomy on rivaroxaban pharmacokinetics, efficacy, and safety.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thromboembolic events are potentially serious complications in patients undergoing bariatric surgery. Several studies have investigated the use of rivaroxaban in patients undergoing bariatric surgery. Further evidence is required to determine whether postsurgical anatomical and physiological changes affect the pharmacokinetics of rivaroxaban. This study aimed to investigate the pharmacokinetic, efficacy, and safety of rivaroxaban in patients who underwent sleeve gastrectomy surgery. Methods: Included patients who admitted for sleeve gastrectomy surgery and were scheduled to receive prophylactic doses of rivaroxaban. Pre- and post-operative rivaroxaban plasma concentrations were determined. Efficacy and safety were assessed 6 and 9 months after surgery. Results: Twenty patients (40% males) were included in the study. The average body weight was 117.6 ± 21.2 kg. The average AUC values before, after, and 7-day after bariatric surgery were 5.83 (1.23), 5.34 (1.87), and 6.29 (2.12) μg·h mL Conclusion: Rivaroxaban 10 mg shows promise as a potential medication for VTE prophylaxis after bariatric surgery. However, future studies with larger, more diverse populations are needed to confirm these findings and strengthen their applicability in clinical practice and to determine the optimal dosage and long-term safety profile in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.